On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19.

The research was part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonixﾒs TNX-1800, a live replicating, attenuated virus vaccine designed to protect against COVID-19.